---
title: "Johnson & Johnson's bladder cancer therapy approved by the U.S. FDA"
description: "Johnson & Johnson's Inlexzo drug delivery system has been approved by the U.S. FDA for the treatment of bladder cancer, providing patients with a non-surgical treatment option. According to mid-term s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256761490.md"
published_at: "2025-09-10T13:14:40.000Z"
---

# Johnson & Johnson's bladder cancer therapy approved by the U.S. FDA

> Johnson & Johnson's Inlexzo drug delivery system has been approved by the U.S. FDA for the treatment of bladder cancer, providing patients with a non-surgical treatment option. According to mid-term study data, over 82% of patients showed no signs of cancer after treatment, and more than half of the patients had no cancer recurrence within a year. Guggenheim analyst Vamil Divan estimates that Inlexzo's potential revenue could reach approximately $3.4 billion by 2040

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system named Inlexzo for the treatment of a type of bladder cancer, providing patients with a potential non-surgical option. The approval of Inlexzo is based on data from a mid-stage study, in which over 82% of patients showed no signs of cancer after receiving Inlexzo treatment, with more than half of the patients remaining cancer-free for at least a year. Guggenheim analyst Vamil Divan estimates that Inlexzo's potential revenue could reach approximately $3.4 billion by 2040

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports | Feb 19 (Reuters) - Johnson & Johnsonis preparing a potential sale of the orthopedics unit that it has been planning to s | [Link](https://longbridge.com/en/news/276370994.md) |
| J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC | Johnson & Johnson (J&J) has received FDA approval for a new monthly dosing schedule for its combination therapy Rybrevan | [Link](https://longbridge.com/en/news/276213027.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| AbbVie Says FDA Approves Cancer Combo Therapy | AbbVie Says FDA Approves Cancer Combo Therapy | [Link](https://longbridge.com/en/news/276427063.md) |
| 11:03 ETNew Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults | The National Comprehensive Cancer Network (NCCN) has released new Clinical Practice Guidelines for Pediatric Soft Tissue | [Link](https://longbridge.com/en/news/276145789.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.